Annexon, Inc. (NASDAQ:ANNX - Get Free Report) shares traded down 0.7% during mid-day trading on Tuesday . The company traded as low as $2.70 and last traded at $2.71. 1,256,948 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 1,455,474 shares. The stock had previously closed at $2.73.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the company. Needham & Company LLC dropped their target price on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. HC Wainwright dropped their target price on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.
View Our Latest Research Report on Annexon
Annexon Trading Down 7.9%
The stock has a fifty day moving average of $2.29 and a two-hundred day moving average of $2.75.
Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.07). Equities analysts anticipate that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Annexon
Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets acquired a new stake in shares of Annexon in the 4th quarter valued at $59,000. Legal & General Group Plc increased its stake in shares of Annexon by 516.7% in the 4th quarter. Legal & General Group Plc now owns 85,535 shares of the company's stock valued at $439,000 after buying an additional 71,665 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Annexon in the 4th quarter valued at $252,000. Nuveen Asset Management LLC increased its stake in shares of Annexon by 6.5% in the 4th quarter. Nuveen Asset Management LLC now owns 2,720,485 shares of the company's stock valued at $13,956,000 after buying an additional 164,915 shares during the period. Finally, Janus Henderson Group PLC bought a new position in shares of Annexon in the 4th quarter worth $177,000.
About Annexon
(
Get Free Report)
Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.
See Also
Before you consider Annexon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.
While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
